Predictors of exacerbation in Japanese patients with severe asthma: Analysis of the severe asthma research program (Okayama-SARP) cohort.
Autor: | Higo H; Department of Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan; Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan., Taniguchi A; Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan., Senoo S; Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan., Ozeki T; Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan., Nakamura N; Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan., Atokawa M; Department of Medical Technology, Okayama University Graduate School of Health Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan., Itano J; Department of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center, 4066, Hayashima, Hayashima-cho Tsukubo-gun, Okayama, 701-0304, Japan., Oda N; Department of Internal Medicine, Fukuyama City Hospital, 5-23-1 Zaou-cho, Fukuyama, 721-8511, Japan., Sunami R; Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan., Shiota Y; Department of Respiratory Medicine, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Minami-ku, Okayama, 702-8055, Japan., Arakawa Y; Department of Respiratory Medicine, KKR Takamatsu Hospital, 4-18 Tenjinmae, Takamatsu, 760-0018, Japan., Mori Y; Department of Respiratory Medicine, KKR Takamatsu Hospital, 4-18 Tenjinmae, Takamatsu, 760-0018, Japan., Kunichika N; Department of Respiratory Medicine, Japanese Red Cross Yamaguchi Hospital, 53-1 Yahatanobaba, Yamaguchi, 753-0092, Japan., Takata I; Department of Internal Medicine, Fukuyama City Hospital, 5-23-1 Zaou-cho, Fukuyama, 721-8511, Japan., Suwaki T; Department of Respiratory Medicine, Okayama City Hospital, 3-20-1 Kitanagaseomote-cho, Kita-Ku, Okayama, 700-8557, Japan., Nakanishi N; Department of Respiratory Medicine, Ehime Prefectural Central Hospital, 83 Kasuga-cho, Matsuyama, 790-0024, Japan., Tanimoto Y; Department of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center, 4066, Hayashima, Hayashima-cho Tsukubo-gun, Okayama, 701-0304, Japan., Kanehiro A; Department of Respiratory Medicine, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Minami-ku, Okayama, 702-8055, Japan; Department of Internal Medicine, Himeji St. Mary's Hospital. 650 Nibuno, Himeji, 670-0801, Japan., Maeda Y; Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan., Kiura K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan., Miyahara N; Department of Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan; Department of Medical Technology, Okayama University Graduate School of Health Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. Electronic address: miyahara@md.okayama-u.ac.jp. |
---|---|
Jazyk: | angličtina |
Zdroj: | Respiratory investigation [Respir Investig] 2024 Jul; Vol. 62 (4), pp. 695-701. Date of Electronic Publication: 2024 May 29. |
DOI: | 10.1016/j.resinv.2024.05.014 |
Abstrakt: | Background: Because exacerbation of severe asthma decreases patients' quality of life, this study aimed to identify predictive factors for asthma exacerbation. Methods: Japanese patients with severe asthma requiring treatment according to the Global Initiative for Asthma (GINA) guidelines ≥ Step 4 between January 2018 and August 2021 were prospectively enrolled and followed up for one year at facilities participating in the Okayama Respiratory Disease Study Group (Okayama Severe Asthma Research Program). Results: A total of 85 patients (29 men and 56 women) were included. The median age was 64 (interquartile range [IQR], 51-72) years. Treatment according to GINA Steps 4 and 5 was required in 29 and 56 patients, respectively, and 44 patients (51.8%) were treated with biologics. The median peripheral-blood eosinophil count, fractional exhaled nitric oxide, IgE level, and percent predicted FEV Conclusions: Exacerbation during the previous year, low ACT score, and low %FEV Competing Interests: Declaration of competing interest HH has received grants from Novartis Pharma K.K., outside the submitted work. AK received speaker fees from AstraZeneca K.K., GlaxoSmithKline K.K., Novartis Pharma K.K., and Sanofi K.K., NM received speaker fees from AstraZeneca K.K., Boehringer Ingelheim K.K., GlaxoSmithKline K.K., Novartis Pharma K.K., and Sanofi K.K.. The rest of the authors have no conflicts of interest. (Copyright © 2024. Published by Elsevier B.V.) |
Databáze: | MEDLINE |
Externí odkaz: |